Once the Food and Drug Administration approved Addyi, a failed antidepressant repackaged as a libido pill for women, drug-maker Valeant Pharmaceuticals bought the company selling Addyi for $1 billion. If they were expecting to cash in on a blockbuster drug, early sales aren’t very promising: in the first month, only 227 prescriptions for the drug have been written. [More]
sprout pharmaceuticals
FDA Closer To Approving Twice-Rejected Female Libido Drug
By 6.5.15
Yesterday, a Food and Drug Administration advisory panel recommended that the agency approve a new drug, flibanserin, which would be marketed under the brand name Addyi. In headlines and in news reports, you see references to the drug as a “pink Viagra” or “Viagra for women.” Yet the drug works on the brain, not the genitals, and critics say that its side effects may not be worth its proven benefits. The FDA has already rejected the drug twice. [More]
